New investors include Invus, Pavilion Capital, Oculus co-founder Michael Antonov through his investment fund, Tubus Management, Laurion Capital Management, and others. Previous investors in the round included the Bill and Melinda Gates Foundation Trust, WuXi AppTec's Corporate Venture Fund, Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures).
The funding will support the advancement of Schrödinger's wholly-owned drug discovery pipeline and enable continued expansion of the company's collaborations with biopharma companies worldwide.
These partnerships have already led to two FDA-approved oncology drugs, several clinical-stage assets, and more than two dozen additional programmes moving through discovery and development.
The investment will also support Schrödinger's ongoing research and development efforts to extend the reach of its proprietary technology platform, which integrates novel physics-based molecular simulations and machine learning to enable exploration of vastly more chemical space than is possible through traditional drug discovery methods.
This expanded and accelerated exploration opens new frontiers for discovery of novel compounds for both therapeutic indications and materials design.
Schrödinger has a global business, licensing its computational platform to pharmaceutical, biotechnology, chemical, and electronics companies to accelerate R and D in both drug discovery and materials design.
The company has built a pipeline of therapeutic assets, held both internally and in partnerships, and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.
Schrödinger's investment in basic research continues to drive advances in its computational platform.
Founded in 1990, Schrödinger has nearly 400 employees in its New York City headquarters and around the world.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval